BRPI1015940A2 - métodos e composições de inibidores de pi-3 quinase para tratar fibrose - Google Patents

métodos e composições de inibidores de pi-3 quinase para tratar fibrose

Info

Publication number
BRPI1015940A2
BRPI1015940A2 BRPI1015940A BRPI1015940A BRPI1015940A2 BR PI1015940 A2 BRPI1015940 A2 BR PI1015940A2 BR PI1015940 A BRPI1015940 A BR PI1015940A BR PI1015940 A BRPI1015940 A BR PI1015940A BR PI1015940 A2 BRPI1015940 A2 BR PI1015940A2
Authority
BR
Brazil
Prior art keywords
compositions
kinase inhibitor
treating fibrosis
inhibitor methods
methods
Prior art date
Application number
BRPI1015940A
Other languages
English (en)
Inventor
Robert Kirkman
William Hardie
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Publication of BRPI1015940A2 publication Critical patent/BRPI1015940A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1015940A 2009-04-09 2010-04-08 métodos e composições de inibidores de pi-3 quinase para tratar fibrose BRPI1015940A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16790509P 2009-04-09 2009-04-09
US23574009P 2009-08-21 2009-08-21
PCT/US2010/030420 WO2010118250A2 (en) 2009-04-09 2010-04-08 Methods and compositions of pi-3 kinase inhibitors for treating fibrosis

Publications (1)

Publication Number Publication Date
BRPI1015940A2 true BRPI1015940A2 (pt) 2016-04-19

Family

ID=42936877

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015940A BRPI1015940A2 (pt) 2009-04-09 2010-04-08 métodos e composições de inibidores de pi-3 quinase para tratar fibrose

Country Status (10)

Country Link
US (1) US20120046333A1 (pt)
EP (1) EP2416771A4 (pt)
JP (1) JP2012523429A (pt)
KR (1) KR20120018761A (pt)
CN (1) CN102395363A (pt)
AU (1) AU2010234360A1 (pt)
BR (1) BRPI1015940A2 (pt)
CA (1) CA2754343A1 (pt)
MX (1) MX2011010631A (pt)
WO (1) WO2010118250A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727478A (zh) * 2012-06-14 2012-10-17 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治肾纤维化药物中的应用
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
NZ723035A (en) 2014-01-28 2022-07-01 Buck Inst Res Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
JP2022065212A (ja) * 2019-02-28 2022-04-27 国立大学法人京都大学 組織線維化による疾患の予防又は治療のための医薬
WO2020201073A1 (en) * 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
CN101180055A (zh) * 2005-05-27 2008-05-14 拜耳医药保健股份公司 用于治疗疾病的包含二芳基脲的组合治疗
WO2006125539A2 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
PL1965790T3 (pl) * 2005-12-30 2012-05-31 Arizona Board Of Regents Acting On Behalf Of The Univ Of Arizona Metabolity analogów wortmaniny i sposoby ich stosowania
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Also Published As

Publication number Publication date
WO2010118250A2 (en) 2010-10-14
EP2416771A4 (en) 2012-10-31
JP2012523429A (ja) 2012-10-04
CA2754343A1 (en) 2010-10-14
KR20120018761A (ko) 2012-03-05
US20120046333A1 (en) 2012-02-23
CN102395363A (zh) 2012-03-28
AU2010234360A1 (en) 2011-09-29
EP2416771A2 (en) 2012-02-15
WO2010118250A3 (en) 2011-03-31
MX2011010631A (es) 2012-01-20

Similar Documents

Publication Publication Date Title
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
BRPI0918970A2 (pt) algoritmo para projeto de inibidores irreversíveis
BRPI0914652A2 (pt) compostos e composições como inibidores de quinase
SMT201400133B (it) Composti e composizioni come inibitori di protein chinasi
ATE522535T1 (de) Pyrrolotriazin-kinasehemmer
BRPI0915205A2 (pt) compostos e composições úteis para o tratamento de malária
BRPI0912668A2 (pt) composto e composições como inibidores de quinase
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI1009112A2 (pt) inibidores de tirosina quinase de bruton
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BRPI0911228A2 (pt) compostos e composições como inibidores de proteínas quinase
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
BRPI0915984A2 (pt) método para inibição da corrosão
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0910979A2 (pt) compostos e composições como inibidores de quinase
DK2246336T3 (da) Fibroseinhibitor
BRPI0922880A2 (pt) compostos inibidores de quinase
BRPI0918564A2 (pt) inibidores
BRPI1015367A2 (pt) imidazotiodiazois para uso como inibidores de cinase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.